May 2025 monthly summary for hartwigmedical/actin: Delivered WGTS mode report enhancement by adding gene expression data points and alternative splice junctions to the predicted tumor origin section, ensuring WGTS samples reflect molecular characteristics in ACTIN reports. This improvement strengthens report fidelity and supports more accurate tumor origin inference across WGTS datasets. Major bugs fixed: none reported. Overall impact: improved clinical decision support through richer molecular data in reports and better traceability with the commit ACTIN-164. Technologies/skills demonstrated: data integration, report generation, molecular data handling, and version-controlled development.

April 2025 performance summary for hartwigmedical development across actin, scripts, and hmftools. Focused on data quality, pipeline reliability, and model/data model compatibility to accelerate decision-making and reduce risk in clinical data processing. Delivered impactful features, fixed key data issues, and strengthened documentation to support production-ready releases.

March 2025 performance for hartwigmedical/actin focused on delivering critical feature capabilities, stabilizing data handling through bug fixes, and elevating test quality and documentation to improve maintainability and onboarding. The work directly enhances patient data classification, trial eligibility determination, and clinician-facing risk assessment, enabling faster, more reliable decision making.

February 2025 monthly summary for hartwigmedical/actin: Delivery focus centered on robust data processing improvements, richer molecular analytics, and expanded data ingestion capabilities to support more accurate patient histories and research workflows. The work emphasized quality, reliability, and business value through refactoring, test coverage, and new metrics that enable deeper insights.